Evidence map›Paper›PMID 22402934›Full record

Trial reportVascular medicine (London, England)2012

Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.

W Schuyler Jones, Brian D Duscha, Jennifer L Robbins, Natasha N Duggan, Judith G Regensteiner, William E Kraus, William R Hiatt, Ayotunde O Dokun, Brian H Annex

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Vascular medicine (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. New horizons in nuclear cardiology: Imaging of peripheral arterial disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Skeletal Muscle Pathology in Peripheral Artery Disease: A Brief Review.Arteriosclerosis, thrombosis, and vascular biology · 2020
    Review
  10. Article
  11. Article
  12. Review
  13. Antiangiogenic VEGFCirculation · 2019
    Article
  14. A computational analysis of pro-angiogenic therapies for peripheral artery disease.Integrative biology : quantitative biosciences from nano to macro · 2018
    Article
  15. Review
  16. Review
  17. Systems Pharmacology of VEGF165b in Peripheral Artery Disease.CPT: pharmacometrics & systems pharmacology · 2017
    Article
  18. Review
  19. WNT5A regulates adipose tissue angiogenesis via antiangiogenic VEGF-AAmerican journal of physiology. Heart and circulatory physiology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

W Schuyler JonesDivision of Cardiology, Duke University Medical Center, Durham, NC, USA. schuyler.jones@duke.edu
Brian D Duscha
Jennifer L Robbins
Natasha N Duggan
Judith G Regensteiner
William E Kraus
William R Hiatt
Ayotunde O Dokun
Brian H Annex
Duke Medical Center · USUniversity of Virginia · USUniversity of Colorado Denver · US

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
Angiogenesis and Mechanisms of Exercise Training in Peripheral Arterial DiseaseR01HL075752 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H · 2003 to 2007
$4.2M
NHLBI NIH HHS 1R01 HL101200S1NHLBI NIH HHS R01 HL075752NHLBI NIH HHS R01 HL101200NHLBI NIH HHS R01 HL75752
6 · The paper itself

Abstract

The aims of this study were twofold: (1) to identify whether peripheral artery disease (PAD) patients had increased muscle concentration of angiogenic VEGF-A, anti-angiogenic VEGF₁₆₅b or VEGF receptor 1 (VEGF-R1) when compared with control subjects, and (2) to evaluate whether exercise training in PAD patients was associated with changes in muscle concentration of VEGF-A, VEGF₁₆₅b or VEGF-R1. At baseline, 22 PAD and 30 control subjects underwent gastrocnemius muscle biopsy. Twelve PAD patients were treated with supervised exercise training (SET) and underwent muscle biopsy after 3 weeks and 12 weeks of training and had sufficient tissue to measure VEGF-A, VEGF₁₆₅b and VEGF-R1 concentrations in skeletal muscle lysates by ELISA. Muscle concentrations of VEGF-A and VEGF₁₆₅b were similar in PAD patients versus controls at baseline. At both time points after the start of SET, VEGF-A levels decreased and there was a trend towards increased VEGF₁₆₅b concentrations. At baseline, VEGF-R1 concentrations were lower in PAD patients when compared with controls but did not change after SET. Skeletal muscle concentrations of VEGF-A are not different in PAD patients when compared with controls at baseline. SET is associated with a significant reduction in VEGF-A levels and a trend towards increased VEGF₁₆₅b levels. These somewhat unexpected findings suggest that further investigation into the mechanism of vascular responses to exercise training in PAD patients is warranted.

Indexed as

Exercise TherapyNeovascularization, PhysiologicAgedAnalysis of VarianceBiopsyCapillariesColoradoEnzyme-Linked Immunosorbent AssayExercise ToleranceFemaleHumansIntermittent ClaudicationMaleMiddle AgedMuscle, SkeletalNorth CarolinaFLT1 protein, humanVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1VEGFA protein, human

Identifiers

PMID22402934
PMCPMC3609421
OpenAlexW2145884868

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.